<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-23T11:09:43+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【招募患者】AB-106 治疗携带NTRK 融合基因的局部进展或全身转移的实体瘤受试者的一项Ⅱ期、多中心、开放、篮式研究</title>
    <updated>2020-11-23T08:09:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/L9o59_RokkzPCnHQGpTv1A</id>
    <link href="https://mp.weixin.qq.com/s/L9o59_RokkzPCnHQGpTv1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】注射用紫杉醇（白蛋白结合型）在乳腺癌患者中的随机、开放、单剂量、多中心、两周期、两交叉生物等效性研究</title>
    <updated>2020-11-22T08:34:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/xq9emeEX12CbhSknO0oAog</id>
    <link href="https://mp.weixin.qq.com/s/xq9emeEX12CbhSknO0oAog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】对比DCC-2618与舒尼替尼在伊马替尼治疗后的胃肠道间质瘤中的有效性、安全性的随机、开放、多中心II期临床研究</title>
    <updated>2020-11-21T07:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/QeYCj68y4Yoz1w2GeM5iqQ</id>
    <link href="https://mp.weixin.qq.com/s/QeYCj68y4Yoz1w2GeM5iqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在轻中度特应性皮炎患者中评估 2% CRISABOROLE 软膏疗效和安全的Ⅲ期、多中心、随机、双盲、赋形剂对照研究</title>
    <updated>2020-11-21T07:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/Ny_lztlrdGPEx1hDHwt5gw</id>
    <link href="https://mp.weixin.qq.com/s/Ny_lztlrdGPEx1hDHwt5gw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【合源CAR-T招募3】CNCT19细胞注射液治疗复发或难治性非霍奇金淋巴瘤的II期临床试验</title>
    <updated>2020-11-20T07:28:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/1KDkebBJhbnavEPuumHi1w</id>
    <link href="https://mp.weixin.qq.com/s/1KDkebBJhbnavEPuumHi1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价福瑞他恩（KX-826）酊治疗中国成年男性雄激素性秃发（AGA）的安全性、有效性的II期临床试验方案</title>
    <updated>2020-11-20T07:28:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ucTM7FvQYts7oTWB2FlMhg</id>
    <link href="https://mp.weixin.qq.com/s/ucTM7FvQYts7oTWB2FlMhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】比较注射用醋酸戈舍瑞林缓释微球（LY01005）和诺雷得治疗乳腺癌有效性和安全性的多中心、随机、开放Ⅲ期临床研究</title>
    <updated>2020-11-19T07:48:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/l3OY2gWCVpqlzwEA5Yqtuw</id>
    <link href="https://mp.weixin.qq.com/s/l3OY2gWCVpqlzwEA5Yqtuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【神州细胞PD-1招募患者6】评估 SCT-I10A 联合 SCT510对比索拉非尼一线治疗肝癌的随机、开放Ⅱ/Ⅲ期临床研究</title>
    <updated>2020-11-18T07:49:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/PlIYXGad8oOJh8Md3dcueA</id>
    <link href="https://mp.weixin.qq.com/s/PlIYXGad8oOJh8Md3dcueA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项旨在评估奥希替尼联合或不联合铂类加培美曲塞作为一线治疗在EGFR突变非小细胞肺癌疗效的III期、开放、随机研究</title>
    <updated>2020-11-17T07:32:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/ZfbNdl4y2UFAuCeNSnt07Q</id>
    <link href="https://mp.weixin.qq.com/s/ZfbNdl4y2UFAuCeNSnt07Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【恒瑞PDL-1、TGFβ双抗招募患者4】SHR-1701单药或联合化疗治疗III期非小细胞肺癌的开放性、多中心II期临床研究</title>
    <updated>2020-11-16T07:50:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/gpeYz2qUVeW7zbasrwujFw</id>
    <link href="https://mp.weixin.qq.com/s/gpeYz2qUVeW7zbasrwujFw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项在复发或难治性B细胞非霍奇金淋巴瘤患者中评估REGN1979的抗肿瘤活性和安全性的开放性研究</title>
    <updated>2020-11-15T08:33:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/eQBtOQTMXnycIlEYJOTp9w</id>
    <link href="https://mp.weixin.qq.com/s/eQBtOQTMXnycIlEYJOTp9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价 ICP-022治疗初治的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机、对照、开放性、多中心III期临床试验</title>
    <updated>2020-11-14T08:38:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/esLbAOxLzZeo-xnOuCa04w</id>
    <link href="https://mp.weixin.qq.com/s/esLbAOxLzZeo-xnOuCa04w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>